Generic drug
Entecavir price, strengths & recalls
Generic of Baraclude
Pharmacies pay $7.38 for 30 tablets of Entecavir 0.5 mg tablet this week, and from $7.38 to $10.74 across its 2 priced strengths and forms. 11 manufacturers make it. 4 recalls are ongoing. Its official label last changed on January 13, 2025.
4 open recallsGeneric- Fair cash price
- $18.99
- Strengths
- 2
- Makers
- 11
- Updated
- Nov 11
Entecavir price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 0.5 mg tablet | $0.2460 | $7.38 / 30 tablets |
| 1 mg tablet | $0.3579 | $10.74 / 30 tablets |
Brand names of entecavir
A brand and its generic share the active ingredient; the generic is almost always far cheaper.
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Entecavir
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS. ENTECAVIR tablets, for oral use Initial U.S. Approval: 2005
WARNING: SEVERE ACUTE EXACERBATIONS OF HEPATITIS B, PATIENTS CO-INFECTED WITH HIV AND HBV, AND LACTIC ACIDOSIS AND HEPATOMEGALY
WARNING: SEVERE ACUTE EXACERBATIONS OF HEPATITIS B, PATIENTS CO-INFECTED WITH HIV AND HBV, and LACTIC ACIDOSIS AND HEPATOMEGALY
Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including entecavir. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, initiation of anti-hepatitis B therapy may be warranted
[see Warnings and Precautions (
5.1)].
Limited clinical experience suggests there is a potential for the development of resistance to HIV (human immunodeficiency virus) nucleoside reverse transcriptase inhibitors if entecavir is used to treat chronic hepatitis B virus (HBV) infection in patients with HIV infection that is not being treated. Therapy with entecavir is not recommended for HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART)
[see Warnings and Precautions (
5.2)].
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogue inhibitors alone or in combination with antiretrovirals
[see Warnings and Precautions (
5.3)].
WARNING: SEVERE ACUTE EXACERBATIONS OF HEPATITIS B, PATIENTS CO-INFECTED WITH HIV AND HBV, and LACTIC ACIDOSIS AND HEPATOMEGALY
See full prescribing information for complete boxed warning.•
Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including entecavir. Hepatic function should be monitored closely for at least several months after discontinuation. Initiation of anti-hepatitis B therapy may be warranted. (
5.1)
•
Entecavir is not recommended for patients co-infected with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) who are not also receiving highly active antiretroviral therapy (HAART), because of the potential for the development of resistance to HIV nucleoside reverse transcriptase inhibitors. (
5.2)
• Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogue inhibitors. (
5.3)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA021797 · Bristol Myers Squibb
- First approved
- March 29, 2005 (21 years ago)
- Latest approved change
- August 18, 2026
- Approved label
- PDF, Aug 20, 2026
- Generic makers
- 8 approved generic applications on the market
Entecavir questions
How much does entecavir cost without insurance?
Pharmacies pay about $7.38 for 30 tablets of entecavir 0.5 mg tablet ($0.2460 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $18.99. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
What is the brand name of entecavir?
Entecavir is sold as Baraclude. The generic has the same active ingredient and usually costs far less.
Is entecavir in shortage?
No shortage is reported for entecavir right now. We check the national shortage list every day.
Has entecavir been recalled?
6 recalls on record, 4 ongoing. Recalls name specific lots - check yours.
When did the entecavir label last change?
The official label was last updated on January 13, 2025 (version 4). See what changed.
Talk about entecavir
No comments yet. Questions, tips, what worked for you - start the conversation.